Sacituzumab govitecan (Trodelvy®). HTA ID: 23079

Assessment Status Rapid Review Complete
HTA ID 23079
Drug Sacituzumab govitecan
Brand Trodelvy®
Indication Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
Assessment Process
Rapid review commissioned 21/12/2023
Rapid review completed 26/01/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sacituzumab govitecan compared with the current standard of care.